OncoGenex Pharmaceuticals Hits New 12-Month Low at $3.26 (OGXI)
OncoGenex Pharmaceuticals (NASDAQ:OGXI) hit a new 52-week low during trading on Monday , American Banking News reports. The stock traded as low as $3.26 and last traded at $3.32, with a volume of 101,868 shares traded. The stock had previously closed at $3.35.
A number of analysts have recently weighed in on OGXI shares. Analysts at Stifel Nicolaus cut their price target on shares of OncoGenex Pharmaceuticals from $21.00 to $9.00 in a research note on Tuesday, April 29th. They now have a “buy” rating on the stock. Separately, analysts at RBC Capital downgraded shares of OncoGenex Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research note on Tuesday, April 29th. They now have a $4.50 price target on the stock, down previously from $19.00. Finally, analysts at Needham & Company LLC downgraded shares of OncoGenex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 28th. They now have a $14.00 price target on the stock, down previously from $30.00. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $11.88.
The stock has a 50-day moving average of $4.10 and a 200-day moving average of $8.6. The company’s market cap is $51.6 million.
OncoGenex Pharmaceuticals (NASDAQ:OGXI) last announced its earnings results on Wednesday, April 30th. The company reported ($0.59) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.50) by $0.09. On average, analysts predict that OncoGenex Pharmaceuticals will post $-2.07 earnings per share for the current fiscal year.
OncoGenex Pharmaceuticals, Inc (NASDAQ:OGXI) is a biopharmaceutical company engaged in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.